Patents for A61P 19 - Drugs for skeletal disorders (81,981)
06/2002
06/26/2002CN1355036A Ointment for treating ostalgia and its preparing process
06/26/2002CN1355029A Ointment for treating hyperosteogency
06/26/2002CN1355021A Percutaneous medicine of strychnine (toxiferine or securinine) and salt thereof
06/26/2002CN1086700C Benzothiophene compounds, intermediates, composition, and methods
06/25/2002US6410782 Bioavailability; side effect reduction; mixture with an aminoalcohol
06/25/2002US6410780 C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
06/25/2002US6410729 Substituted pyrimidine compounds and methods of use
06/25/2002US6410728 Oxazolidinone chemotherapeutic agents
06/25/2002US6410588 Use of cannabinoids as anti-inflammatory agents
06/25/2002US6410564 Naphthyl compounds, intermediates, processes, compositions, and methods
06/25/2002US6410555 Antiepileptic agents; headaches
06/25/2002US6410551 Bronchodilator
06/25/2002US6410540 Inhibitors of p38-αkinase
06/25/2002US6410526 Bone disorders; restenosis; vision disorders; anticholesterol agents; anticancer, antitumor agents
06/25/2002US6410520 Heating in aqueous solution
06/25/2002US6410512 Inhibitors of proteasomal activity for stimulating hair growth
06/25/2002US6410508 Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
06/25/2002US6410316 Methods for producing a vector producing cell line utilizing a high multiplicity of transduction
06/25/2002US6410289 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
06/25/2002US6410269 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
06/25/2002CA2215210C Polyphenol fractions of tea, the use thereof and formulations containing them
06/25/2002CA2140281C Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis
06/20/2002WO2002048337A2 Secreted human proteins
06/20/2002WO2002048117A1 Quinazolinone derivatives
06/20/2002WO2002048114A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents
06/20/2002WO2002048096A1 Hydrazone derivatives and use thereof in medicines
06/20/2002WO2002047762A1 Serine protease inhibitors
06/20/2002WO2002047708A2 Selective cox-2 inhibition from edible plant extracts
06/20/2002WO2002047707A2 Selective cox-2 inhibition from non-edible plant extracts
06/20/2002WO2002047706A2 Selective cox-2 inhibition from plant extracts
06/20/2002WO2002047705A2 Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use
06/20/2002WO2002047704A1 Herbal pharmaceutical compositions for treating immunological disorders
06/20/2002WO2002047702A1 Compositions for inducing secretion of insulin-like growth factor-1
06/20/2002WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
06/20/2002WO2002047697A2 Fractions of snake blood, their preparation and use as therapeutic agents
06/20/2002WO2002047696A1 Use of low molecular heparin for treating osteoarthritis
06/20/2002WO2002047692A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis
06/20/2002WO2002047686A1 Substituted-4-quinolones
06/20/2002WO2002047673A2 Methods and compositions to treat conditions associated with neovascularization
06/20/2002WO2002047493A2 Health promoting compositions
06/20/2002WO2002030888A3 Tricyclic compounds and uses thereof
06/20/2002WO2002028905A3 Human anti-cd40 antibodies
06/20/2002WO2002024681A3 Pyrazine derivatives as modulators of tyrosine kinases
06/20/2002WO2002016436A3 ANTIBODIES TO HUMAN IL-1$g(b)
06/20/2002WO2001089570A3 Combination of growth hormone secretagogues and antidepressants
06/20/2002WO2001087977A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
06/20/2002WO2001085942A3 Cytoskeleton-associated proteins
06/20/2002WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
06/20/2002WO2001044445A8 Human lyases and associated proteins
06/20/2002WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
06/20/2002WO2000067734A3 Use of phthalazine derivatives
06/20/2002WO2000061750A9 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
06/20/2002WO2000061596A8 50 human secreted proteins
06/20/2002WO2000052210A9 Methods for targeting rna molecules
06/20/2002US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis
06/20/2002US20020077461 Pharmaceutical formulation
06/20/2002US20020077460 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
06/20/2002US20020077356 Nonsteroidal antiinflammatory agents
06/20/2002US20020077351 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation
06/20/2002US20020077339 Chemokine receptor binding heterocyclic compounds
06/20/2002US20020077337 Chemical compounds
06/20/2002US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2)
06/20/2002US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis
06/20/2002US20020077321 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis
06/20/2002US20020077319 Combination of GABA agonists and aldose reductase inhibitors
06/20/2002US20020077304 Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
06/20/2002US20020077281 Fracture healing using pthrp analogs
06/20/2002US20020077273 Methods of using agents that modulate bone formation and inhibit adipogenesis
06/20/2002US20020076810 Biocompatible composition in the form of a gel for use in the treatment of, inflammation,tumors and bone disorders
06/20/2002US20020076796 2786, a novel human aminopeptidase
06/20/2002US20020076793 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4
06/20/2002US20020076766 Novel glucosaminidase
06/20/2002US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain
06/20/2002US20020076702 Evaluating prostaglandin response to preferential modulators; obtain sample, incubate with modulator, compare profile with control, determine if human had prostaglandin response to moduator based on differences in control and sample profiles
06/20/2002US20020076447 Suspension or particle-solvent mixture system of zinc-containing calcium phosphate microparticle, and therapeutic agent for treating zinc deficiency
06/20/2002US20020076418 Use of strains of parapoxvirus ovis against organ fibrosis
06/20/2002US20020076399 Treatment of immune diseases
06/20/2002DE10063173A1 Harnstoff- und Urethanderivate Urea and urethane
06/20/2002DE10060809A1 Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker Substituted anthranilic acids, their use as a medicament or diagnostic, and she containing drug, as well as a pharmaceutical combination preparation with a sodium / hydrogen exchange (NHE) blockers
06/20/2002CA2431852A1 Herbal pharmaceutical compositions for treating immunological disorders
06/20/2002CA2431709A1 Use of low molecular heparin for treating osteoarthritis
06/20/2002CA2431406A1 Quinazolinone derivatives
06/20/2002CA2430151A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents
06/20/2002CA2428216A1 Secreted proteins
06/19/2002EP1215214A1 Novel polypeptide
06/19/2002EP1215203A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
06/19/2002EP1214894A1 Food formulations with a high calcium content
06/19/2002EP1214452A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes
06/19/2002EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
06/19/2002EP1214422A1 Phosphatases which activate map kinase pathways
06/19/2002EP1214409A1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
06/19/2002EP1214396A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic
06/19/2002EP1214348A2 Parathyroid hormone analogues for the treatment of osteoporosis
06/19/2002EP1214346A1 A novel angiogenesis inhibitor
06/19/2002EP1214344A1 Dipeptidyl peptidases
06/19/2002EP1214337A2 Proteins associated with cell differentiation
06/19/2002EP1214325A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
06/19/2002EP1214324A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
06/19/2002EP1214318A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
06/19/2002EP1214305A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation